[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastatic-malignant-neoplasm-in-the-bone\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastatic-malignant-neoplasm-in-the-bone":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,72,110,135,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100351619","low-dose-radiotherapy-in-treating-painful-bone-metastases-in-patients-with-multiple-myeloma-100351619",false,"NCT03858205","Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma","Phase II Multi-Institutional Study of Low-Dose (2Gy) Palliative Radiotherapy in the Treatment of Symptomatic Bone Metastases From Multiple Myeloma","Inclusion Criteria:\n\n* Histologic diagnosis of multiple myeloma\n* Painful bone metastasis (index lesion) that has a radiographic correlate\n* Patient may have had any number of prior chemotherapy\u002Fimmunotherapy regimens (changes to systemic therapy or use of bisphosphonates for 4 weeks before and after RT are allowed, but recording of these changes must be made so it can be accounted for)\n* Eastern Cooperative Oncology Group (ECOG) 0-2\n* Brief Pain Inventory (BPI) score \\>= 2\n* Ability to understand and the willingness to sign a written informed consent\n\nExclusion Criteria:\n\n* Patients will be ineligible if the index lesion has received prior radiation therapy or prior palliative surgery. Patients may have received prior palliative or primary radiotherapy or surgery to other parts of the body, as long as the index lesion was not in the prior radiation fields and has not received prior palliative surgery\n* Patients will also be ineligible if there is pathologic fracture or impending fracture at the site of the index lesion or planned surgical fixation of the bone at the index lesion\n* Patients with clinical or radiographic evidence of spinal cord or cauda equina compression\u002Feffacement from the index lesion, and\u002For with index lesions located at the skull base or orbital lesions\n* Patients must not be pregnant","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiation.",[26,27,28],"Bone Pain","Metastatic Malignant Neoplasm in the Bone","Plasma Cell Myeloma","RECRUITING","2026-06-03",{"date":32,"type":33},"2026-06-05","ACTUAL",{"date":35,"type":33},"2019-03-11",{"date":37,"type":20},"2027-03-11",{"name":39,"class":40},"University of Southern California","OTHER",9,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100591576","phase-1-testing-the-safety-of-the-anti-cancer-drug-sn-117m-dtpa-for-advanced-cancers-that-have-spread-to-bones-100591576","NCT06982222","Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones","A First-in-Human Dose-Finding Phase I Study of Bone-targeted High Specific Activity Stannic-117m Pentatate (Sn-117m-DTPA) in Solid Tumors With Skeletal Metastases","Inclusion Criteria:\n\n* Histologically documented prostate, breast, or non-small cell lung cancer (NSCLC)\n* Metastatic disease in bone only (patients with visceral disease, cutaneous disease or malignant lymph nodes \\> 3 cm in largest diameter are not eligible)\n* Documented disease progression (1 or more new bone lesion or enlargement of existing bone lesion, identified by Tc-99m bone scintigraphy or CT scan, magnetic resonance imaging \\[MRI\\], fludeoxyglucose F-18 \\[FDG\\] PET CT scan or PSMA PET CT scan)\n* Must have progression on at least one line of standard of care systemic therapy. There are no maximum number of prior therapies\n* Patients with prostate cancer\n\n  * Patients with prostate adenocarcinoma, their disease must be characterized as: must have prior bilateral orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum testosterone (\\\u003C 50 ng\u002FdL or \\\u003C 1.7 nmol\u002FL)\n  * Serum PSA progression, defined as two consecutive increases in PSA over a previous reference value, each measurement at least one week apart or, PSA progression ≥ 25% after 12 weeks of current standard of care (SOC) therapy (Scher et al., 2016)\n  * Patients must have a baseline positive PSMA-PET scan. Patients must have progressed on at least one line of hormone therapy: Androgen receptor signaling inhibitors (ARSIs) therapy such as enzalutamide, apalutamide, darolutamide, or androgen synthesis blockers (abiraterone acetate). There are no minimum number of prior hormone therapies\n  * Progression after chemotherapy (docetaxel or cabazitaxel) in patients who were chemotherapy candidates is allowed. However, prior chemotherapy is not required\n  * Progression after a prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (for example: lutetium-177 vipivotide tetraxetan \\[Pluvicto\\]) is allowed but not required\n  * Allowed to have received one prior cytotoxic chemotherapy treatment and one radiopharmaceutical therapy treatment OR no more than two cytotoxic chemotherapy treatments (for patients who have not received a prior radiopharmaceutical therapy treatment)\n* Patients with breast cancer\n\n  * Patients with any estrogen receptor (ER)\u002Fprogesterone receptor (PR)\u002Fhuman epidermal growth factor receptor 2 (HER2) receptor status are eligible\n  * Patients with hormone-receptor positive disease should have progressed on at least one or more prior line(s) of SOC anti-estrogen therapy and a cyclin-dependent kinase (CDK)4\u002F6 inhibitor (except if patient had a contraindication or intolerable toxicity with the use of these agents)\n  * Patients with HER2 positive disease should have progressed on at least one or more line(s) of SOC anti-HER2 therapy.\n  * Patients with triple negative disease should have progressed on at least one more line(s) of SOC chemotherapy\n  * Previous radiation and chemotherapy are allowed\n* Patients with non-small cell lung cancer (NSCLC)\n\n  * Patients with NSCLC should have progressed on at least one or more prior line(s) of SOC therapy, including chemotherapy and\u002For immunotherapy or targeted therapy if they qualify\n* Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of Sn-117m-DTPA in patients \\\u003C 18 years of age, children are excluded from this study\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%)\n* Absolute neutrophil count ≥ 1,000\u002FmcL\n* Platelets ≥ 75,000\u002FmcL\n* Hemoglobin \\> 9 g\u002FdL\n* Total bilirubin ≤ 2.5 x institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT)(serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 5 x institutional ULN\n* Creatinine ≤ 1.7 mg\u002FdL OR glomerular filtration rate (GFR) ≥ 50 mL\u002Fmin\u002F1.73 m\\^2\n* Patients must be taking a bone health agent (bisphosphonates or denosumab) for at least one (1) month prior to enrollment\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better\n* The effects of Sn-117m-DTPA on the developing human fetus are unknown. For this reason and because radionucleotides are known to be teratogenic, male participants and their female partners of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. A woman of childbearing potential is a premenopausal female capable of becoming pregnant. Should a woman of childbearing potential become pregnant or suspect she is pregnant while her male partner is participating in this study, she should inform her treating physician immediately. Both men and women of childbearing potential treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 6 months after completion of Sn-117m-DTPA administration. For prostate cancer patients, androgen deprivation therapy is considered adequate contraception\n* Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign if the patient is physically (not mentally) not capable of signing\n\nExclusion Criteria:\n\n* Patients who have not recovered from reversible adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> grade 1) with the exception of alopecia\n* Patients must not have received any investigational agents within 4 weeks or 5 half-lives, whichever is shorter, before starting study treatment, nor be scheduled to receive one during the planned treatment period\n* Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Sn-117m-DTPA\n* Patients must not have imminent or established spinal cord compression, pathological fracture in weight bearing bones, or bone lesion with soft tissue component unless treated as appropriate with radiation and\u002For surgery before starting on this study\n* Patients must not have received prior systemic radiotherapy with strontium-89, samarium-153, rhenium-186, rhenium-188, or radium-223 dichloride (Xofigo) for the treatment of bony metastases. Prior systemic radiopharmaceutical therapy with lutetium Lu 177 vipivotide tetraxetan (Pluvicto) is permitted, but last treatment must be at least six weeks prior to starting study treatment due to the concern of bone marrow suppression\n* Patients must not have unmanageable urinary incontinence\n* Pregnant women are excluded from this study because Sn-117m-DTPA is a radionucleotide with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Sn-117m-DTPA, breastfeeding should be discontinued if the mother is treated with Sn-117m-DTPA",{"count":50,"type":20},24,[52],"PHASE1","This phase I trial tests the safety, side effects and best dose of tin (Sn)-177m-diethylenetriaminepentaacetic acid (DTPA) and how well it works in treating prostate, breast or non-small cell lung cancer that has spread from where it first started (primary site) to the bones (bone metastases). Sn-117m-DTPA was originally tested in tumors that had spread to the bones to help reduce bone pain. The drug has been improved and is designed to send low-level radiation to tumors in the bone while being gentler on the bone marrow, where blood cells are made. Sn-117m-DTPA may be safe and tolerable, and may slow down or shrink tumors in patients with metastatic prostate, breast, or non-small cell lung cancer that has spread to the bones.",[55,56,57,27,58,59,60],"Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IV Lung Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8","NOT_YET_RECRUITING","2026-05-12",{"date":64,"type":33},"2026-05-13",{"date":66,"type":20},"2026-10-01",{"date":68,"type":20},"2027-02-12",{"name":70,"class":71},"National Cancer Institute (NCI)","NIH",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100415725","cryoablation-combined-with-stereotactic-body-radiation-therapy-for-the-treatment-of-painful-bone-metastases-the-crome-trial-100415725","NCT04693377","Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial","Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases","Inclusion Criteria:\n\n* Patient must have a primary diagnosis of malignancy and radiographic evidence of bone metastases. Eligible tumor histologies include the following malignancies with low alpha\u002Fbeta ratios: renal cell carcinoma, urothelial carcinomas, castration-resistant prostate cancer, sarcoma, thyroid carcinoma, colorectal carcinoma, and melanoma\n* A target lesion the meets the following criteria:\n\n  * The target lesion must be amenable to both cryoablation and SBRT, as determined by the study principal investigators (PIs)\n  * The target lesion must be =\\\u003C 7cm\n  * The pain due to the target lesion must be at least 4\u002F10 based on the BPI pain scale\n  * Pain from the metastatic site must correlate with an identifiable tumor on computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound (US) imaging\n* Life expectancy \\>= 3 months\n* Platelet count \\> 50,000\u002Fmm\\^3 within 6 weeks of screening\n* International normalized ratio (INR) \\\u003C 1.5 within 6 weeks of screening\n* If taking antiplatelet or anticoagulation medication, it must be able to be discontinued 48 hours prior to the procedure or at the discretion of the PI (e.g., aspirin, ibuprofen, low molecular weight heparin \\[LMWH\\] preparations)\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 1 (Karnofsky \\>= 70%) within 6 weeks of screening\n* Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: Women \\\u003C 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization. Women \\>= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\> 1 year ago, had chemotherapy-induced menopause with last menses \\> 1 year ago, or underwent surgical sterilization\n* All lines of prior systemic therapy are permissible. Standard concurrent chemotherapy, immunotherapy, or targeted therapy are permissible\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Prior locoregional therapy to target lesion, including ablation of any modality, embolization, radiation, or surgery\n* Patient may not be receiving any other investigational agents. Standard concurrent chemotherapy, immunotherapy, or targeted therapy will be allowed\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnant or nursing women; women of childbearing potential unless using effective contraception as determined by the investigator\n* Target lesions that involve the spinal column or calvarium\n* Absolute neutrophil count \\\u003C 1000 mm\\^3 within 6 weeks of screening\n* Active infection\n* Presence of confirmed pathologic fracture at the target lesion not amenable to percutaneous stabilization\n* Lesions that involve a weight-bearing long bone of the lower extremity with the tumor causing \\> 50% loss of cortical bone. Lesions involving the hands and feet",{"count":80,"type":20},40,[23],"This trial compares cryoablation combined with stereotactic body radiation therapy to stereotactic body radiation therapy alone to see how well they work in treating patients with pain from cancer that has spread to the bones (bone metastases). Bone is a common site of metastasis in advanced cancer, and bone metastases often result in debilitating cancer-related pain. The current standard of care to treat painful bone metastases is radiation therapy alone. However, many patients do not get adequate pain relief from radiation therapy alone. Another type of therapy that may be used to provide pain relief from bone metastases is cryoablation. Cryoablation is a procedure in which special needles are inserted into the tumor site. These needles grow ice balls at their tips to freeze and kill cancer cells. The goal of this trial is to compare how well cryoablation in combination with radiation therapy works to radiation therapy alone when given to cancer patients to provide pain relief from bone metastases.",[84,85,27,86,87,88,89,90,91,92,93,94,95,96,97,98,60,99],"Castration-Resistant Prostate Carcinoma","Metastatic Colorectal Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Metastatic Prostate Carcinoma","Metastatic Renal Cell Carcinoma","Metastatic Sarcoma","Metastatic Thyroid Gland Carcinoma","Metastatic Urothelial Carcinoma","Stage IV Colorectal Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Stage IVA Colorectal Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Colorectal Cancer AJCC v8","Stage IVC Colorectal Cancer AJCC v8","2026-04-10",{"date":102,"type":33},"2026-04-15",{"date":104,"type":33},"2021-03-16",{"date":106,"type":20},"2027-04-01",{"name":108,"class":40},"M.D. Anderson Cancer Center",1,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":117,"minAge":17,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":120,"phases":4,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100400091","impact-of-dna-repair-pathway-alterations-on-sensitivity-to-radium-223-in-bone-metastatic-castration-resistant-prostate-cancer-100400091","NCT04489719","Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer","The Impact of DNA Repair Pathway Alterations Identified by Circulating Tumor DNA on Sensitivity to Radium-223 in Bone Metastatic Castration-Resistant Prostate Cancer","Inclusion Criteria:\n\n* Patient must be \\>= 18 years of age\n* Patient must have histopathologic diagnosis of prostate cancer\n* Patient must have castration-resistant prostate cancer\n* Patient must have radiographic evidence of bone metastasis\n* Patients must be symptomatic from prostate cancer\n* Patient must have plans to undergo treatment with radium-223\n* Patient must have a PSA level \\>= 10 ng\u002FmL\n* Patient must have castrate testosterone levels demonstrated within the last 3 months prior to screening\n* Patient must have anticipated survival \\> 3 months\n* Patient must be willing and able to authorize consent\n* Patient must be willing and able to comply with the protocol, including follow-up visits\n\nExclusion Criteria:\n\n* Patient must not have visceral metastasis\n* Patients on regimens of radium-223 in combination with other antineoplastic agents are excluded\n\n  \\* Bone-targeted only therapy (e.g. denosumab or zoledronic acid) will be allowed\n* Patients who have received prior radium-223\n* Patients who have received prior platinum containing chemotherapy\n* Absolute neutrophil count (ANC) \\\u003C 1.5 x 10\\^9\u002FL\n* Hemoglobin (HB) \\\u003C 9 g\u002FdL\n* Platelets (PLT) \\\u003C 100 x 10\\^9\u002FL\n* Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation","MALE",{"count":119,"type":20},48,"OBSERVATIONAL","This study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases). Prostate cancer is the most common cancer in men and the second leading cause of cancer death. Furthermore, many men with notably advanced disease have been found to have abnormalities in DNA repair. The purpose of this research is to study the role of a DNA repair pathway in prostate cancer, specifically in response to administration of radium-223, an FDA-approved drug known to cause DNA damage to cancerous cells. Understanding how defects in the DNA repair pathway affects radium-223 treatment of prostate, may help doctors help plan effective treatment in future patients.",[84,27,88,60],[124],"Prostate","2026-02-12",{"date":127,"type":33},"2026-02-17",{"date":129,"type":33},"2021-04-16",{"date":131,"type":20},"2029-08-01",{"name":133,"class":40},"University of Washington",4,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":142,"sex":117,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":120,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":109},"100136749","collecting-and-studying-blood-and-tissue-samples-from-patients-with-locally-recurrent-or-metastatic-prostate-or-bladderurothelial-cancer-100136749","NCT01050504","Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder\u002FUrothelial Cancer","Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy","Inclusion Criteria:\n\n* Patients with localized and\u002For metastatic bladder\u002Furothelial or prostate cancer who have disease in the primary organ, biopsy accessible bone metastases (collaborating radiologists will determine if bone metastasis is appropriate for biopsy) or soft tissue metastases are eligible; men and women without cancer are eligible to have blood or normal tissue collected if acquired as part of non-research procedures (e.g. transurethral resection of the prostate or bladder); in patients without malignancy, no additional tissue beyond that necessary for care will be procured\n* Ability to adequately understand and give informed consent\n* Local or metastatic disease to soft tissue or bone at sites accessible to biopsy with minimal risk of complications Or the ability to obtain tissue with minimal risk of complication from a surgical procedure being conducted as a part of another research study Or for standard of care purposes or patients who have archival tissue collected for research or standard of care who are willing to donate archival tissue for this study\n* Alternatively, men and women without cancer or who are at risk of developing cancer are eligible to have blood or normal tissue collected if acquired; tissue will only be acquired as part of non-research procedures (e.g. transurethral resection of the prostate or bladder; in patients without malignancy, no additional tissue beyond that necessary for care will be procured\n* Platelet count \\> 50,000\n* White blood cell (WBC) \\> 1,500\n* Hemoglobin (Hgb) \\> 8.0\n* International normalized ratio (INR) \\\u003C 1.5\n* Partial thromboplastin time (PTT) \\\u003C 45\n* No history of excessive unexplained bleeding from previous surgery\n\nExclusion Criteria:\n\n* Patients unable to stop chronic anticoagulation with warfarin or Lovenox for less than 3 days\n* Serious or uncontrolled infection\n* Treatment with a vascular endothelial growth factor (VEGF) inhibitor (such as Avastin) within the past 28 days",true,{"count":144,"type":20},1500,"This study collects and studies tissue and blood samples from patients with prostate or bladder\u002Furothelial cancer that has recurred (come back) at or near the same place as the original (primary) tumor or has spread to other parts of the body. Studying samples of blood and tissue samples from patients with prostate or bladder\u002Furothelial cancer in the laboratory may help doctors learn more about new biomarkers, potential drug targets, and resistance developing in response to treatment. It may also help doctors find better ways to treat the cancer.",[147,148,27,149,150,151,152,153,154,155,156],"Localized Renal Pelvis and Ureter Urothelial Carcinoma","Malignant Solid Neoplasm","Metastatic Malignant Neoplasm in the Soft Tissues","Metastatic Renal Pelvis and Ureter Urothelial Carcinoma","Recurrent Bladder Carcinoma","Recurrent Prostate Carcinoma","Recurrent Renal Pelvis and Ureter Urothelial Carcinoma","Stage IV Bladder Cancer AJCC v7","Stage IV Bladder Urothelial Carcinoma AJCC v7","Stage IV Prostate Cancer AJCC v7","2026-01-13",{"date":159,"type":33},"2026-01-15",{"date":161,"type":4},"2009-08",{"date":163,"type":20},"2029-01-31",{"name":133,"class":40},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":173,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":109},"100558312","phase-1-biology-guided-radiation-therapy-for-the-treatment-of-patients-with-bone-metastases-100558312","NCT06549478","Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases","A Pilot Study of BgRT for Bone Metastases","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* Age: ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Pathologic diagnosis of cancer\n* Painful bone metastases from any solid cancers (i.e., a score of at least 2 on a 0-10 scale, 0 representing no pain and 10 representing maximum pain)\n* Concurrent treatment of up to 3 radiation fields is allowed\n* Standardized uptake value maximum (SUVmax) of the target bone lesions on diagnostic PET \\> 6\n* Size of the target bone lesion 1.5-5 cm\n* Pre-screening assessment confirms that the intervention can be administered without exceeding dose constraint guidelines\n* Patients with brain metastases can be included but brain metastases must be treated prior to enrollment and follow up magnetic resonance imaging (MRI) 3 months after treatment shows stable findings\n* Life expectancy ≥ 6 months in the opinion of the treating investigators\n* Off systemic therapy for at least one week prior and one week after study intervention\n* Patients able to complete pain assessment and quality of life surveys who do not have cognitive impairment\n\nExclusion Criteria:\n\n* Patients with prior radiation therapy to the treatment sites\n* Untreated spinal cord compression\n* Pathologic fracture at the evaluated site\n* Serious medical comorbidities precluding radiotherapy\n* Unable to undergo a PET\u002FCT scan\n* Pregnant and\u002For breastfeeding women are excluded from this study as these agents may have the potential for teratogenic or abortifacient effects\n* Judgement by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions, and requirements\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics, patients who exhibit cognitive impairments\u002F who are unable to complete study materials: assessments\u002Fquestionnaires)",{"count":50,"type":20},[52],"This clinical trial tests the safety and effectiveness of a single-dose treatment of biology-guided radiation therapy (BgRT) in treating patients with painful cancer that has spread from where it first started (primary site) to the bone (bone metastases). Bone metastases can result in significant pain and reduction in quality of life. Single fraction radiation therapy (SFRT) can produce equivalent pain relief compared to multi-fraction radiation therapy, but SFRT treatments generally lead to higher rates of retreatment. BgRT is a new and innovative form of radiation delivery that uses a signal generated by positron emission tomography to guide external beam radiation therapy. It is a technology breakthrough that uses live, continuously updated data throughout the entire treatment session to determine exactly where to deliver radiotherapy to biologically active tumors. Giving BgRT may be safe and effective in treating patients with painful bone metastases.",[27,86],"2025-09-14",{"date":178,"type":33},"2025-09-17",{"date":180,"type":33},"2024-07-26",{"date":182,"type":20},"2027-01-26",{"name":184,"class":40},"City of Hope Medical Center"]